59 related articles for article (PubMed ID: 35917132)
1. Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: Results from the MYONET registry.
Hum RM; Lilleker JB; Lamb JA; Oldroyd AGS; Wang G; Wedderburn LR; Diederichsen LP; Schmidt J; Danieli MG; Oakley P; Griger Z; Phuong TNT; Kodishala C; Vazquez-Del Mercado M; Andersson H; De Paepe B; De Bleecker JL; Maurer B; McCann L; Pipitone N; McHugh N; New RP; Ollier WE; Krogh NS; Vencovsky J; Lundberg IE; ; Chinoy H
Rheumatology (Oxford); 2023 Sep; ():. PubMed ID: 37698987
[TBL] [Abstract][Full Text] [Related]
2. Research progress on the dermatomyositis specific autoantibodies and malignancy associated dermatomyositis.
Xu Y; Yang Y; Fan S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1890-1898. PubMed ID: 38448383
[TBL] [Abstract][Full Text] [Related]
3. Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis.
Karasawa R; Yudoh K; Sato T; Tanaka M; Sabbagh SE; Flegel WA; Mammen AL; Jarvis JN; Rider LG;
Rheumatology (Oxford); 2023 Nov; 62(11):3757-3762. PubMed ID: 37144941
[TBL] [Abstract][Full Text] [Related]
4. Anti-SAE dermatomyositis: clinical and histologic characteristics from a monocentric Italian cohort.
Fornaro M; Coladonato L; Giannini M; Napoletano A; Girolamo F; D'Abbicco D; Ruggieri M; Sabella DVA; Iannone F
Clin Exp Rheumatol; 2024 Feb; 42(2):295-301. PubMed ID: 38488098
[TBL] [Abstract][Full Text] [Related]
5. Using autoantibody signatures to define cancer risk in dermatomyositis.
Turnier JL; Kahlenberg JM
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040442
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic anti-TIF1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.
van Erp MAJM; Slaats FMA; Emmen JMA; van Hamont D
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262717
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Disease and Dermatomyositis: A Mini-Review.
Qian J; Xu H
Front Immunol; 2021; 12():747116. PubMed ID: 35095837
[TBL] [Abstract][Full Text] [Related]
8. A Rare Case of Anti-Mi-2 Antibody-Positive Dermatomyositis Associated With Gastrointestinal Stromal Tumor.
Akpoigbe O; Anim-Koranteng C; Tasmin R; Sammut A
J Rheumatol; 2024 May; ():. PubMed ID: 38749561
[TBL] [Abstract][Full Text] [Related]
9. Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review.
Yu K; Wang T; An D; Li X; Tang Z
Semin Arthritis Rheum; 2024 May; 67():152478. PubMed ID: 38833729
[TBL] [Abstract][Full Text] [Related]
10. Issues in the classification of myositis patients: an ongoing process.
Zanframundo G; Selva-O'Callaghan A; González-Gay MÁ; Montecucco C; Cavagna L
Clin Exp Rheumatol; 2024 Feb; 42(2):225-228. PubMed ID: 38372711
[No Abstract] [Full Text] [Related]
11. Anti-Mi-2 antibody-positive dermatomyositis following Spirulina intake.
Kuzumi A; Yoshizaki A; Kawanabe R; Sato S
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38486347
[No Abstract] [Full Text] [Related]
12. TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients.
Nguyen HD; Jouen F; Déchelotte B; Cordel N; Gitiaux C; Bodemer C; Quatier P; Belot A; O'Brien K; Cancemi D; Melki I; Fabien N; Tansley S; Boyer O; Wedderburn LR; Bader-Meunier B;
Rheumatology (Oxford); 2024 Mar; ():. PubMed ID: 38498839
[No Abstract] [Full Text] [Related]
13. Myositis-Related Interstitial Lung Diseases: Diagnostic Features, Treatment, and Complications.
Shappley C; Paik JJ; Saketkoo LA
Curr Treatm Opt Rheumatol; 2019 Mar; 5(1):56-83. PubMed ID: 31984206
[No Abstract] [Full Text] [Related]
14. The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients.
Chen X; Zhang L; Jin Q; Lu X; Lei J; Peng Q; Wang G; Ge Y
Front Immunol; 2022; 13():987841. PubMed ID: 36110863
[TBL] [Abstract][Full Text] [Related]
15. Malignancy in dermatomyositis: a mono-centric retrospective study of 134 patients in China and a potential predictive model.
Tang ZL; Chi CC; Tang ZW; Li XW; Man XY
Front Med (Lausanne); 2023; 10():1200804. PubMed ID: 37359002
[TBL] [Abstract][Full Text] [Related]
16. The associations between myositis autoantibodies and clinical presentations in dermatomyositis.
Su HJ; Chung WH; Lin CY
Australas J Dermatol; 2022 Nov; 63(4):479-487. PubMed ID: 35917132
[TBL] [Abstract][Full Text] [Related]
17. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
19. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
